Serial Stage Venture Partners
Cleveland, OH, United States
Overview
Serial Stage Venture Partners (SSVP) is a venture investor network created for individuals and family office investment managers interested in making self-directed venture capital allocations. SSVP primarily invests in early- to late-stage technology and healthcare companies.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 0
Investment portfolio
- Alphyn Biologics
Participated · Series B · Dec 2025
Alphyn Biologics is a clinical-stage dermatology firm advancing first-in-class Multi-Target Therapeutics based on its Zabalafin Platform. Its lead product, Zabalafin Hydrogel, is designed to simultaneously address the multiple drivers of atopic dermatitis (inflammation, itch, bacteria and dry skin) and molluscum contagiosum virus (virus, itch, inflammation, dermatitis and secondary bacterial infection). The topical candidate aims to provide superior efficacy, better tolerability and the potential for sustained disease control compared with single-target treatments. With the new funding, Alphyn plans to run a global Phase 2b trial in atopic dermatitis, launch a Phase 2 program in molluscum contagiosum and scale its raw-material supply. The company became operational in 2020 and maintains offices in Annapolis, Maryland and Cincinnati, Ohio, with subsidiaries in Australia and Austria. Including the latest round, Alphyn has raised roughly $34 million to date to build a pipeline of dermatologic therapeutics.
Team
No current team members are available.